AstraZeneca's Cambridge site aimed at optimizing R&D operations
- AstraZeneca’s Cambridge Biomedical Campus (CBC) will include an R&D ‘enabling’ building as well as a central courtyard.
- This will be the site for AstraZeneca’s small molecule and biologics R&D activity.
- MedImmune’s biologics research and protein engineering will also be conducted at CBC.
The site is being designed with low rise buildings to be consistent with the surrounding architecture. “Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners to push the boundaries of scientific innovation,” said Mene Pangalos, executive VP of innovative medicines and early development at AstraZeneca.
AstraZeneca says that the move is meant to optimize the company's R&D operations, which are being beefed up internationally. AstraZeneca has facilities in Sweden and Gaithersburg, MD.
- pharmafile.com AstraZeneca reveals Cambridge plans